SCHEMBL5489719

SCHEMBL5489719

COC(=O)c1sccc1CSc1nc2cc(C)c(C)cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
RAB9A P51151 5/20 0.47
GFER P55789 1/20 0.47
LMNA P02545 4/20 0.46
HTT P42858 4/20 0.46
GAA P10253 2/20 0.46
TSHR P16473 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
RECQL P46063 1/20 0.44
ALDH1A1 P00352 4/20 0.44
CYP1A2 P05177 2/20 0.42
CYP2E1 P05181 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C8 P10632 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2B6 P20813 2/20 0.42
CYP2C19 P33261 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475685 0.85 RAB9A (0.59) MAPTRAB9ALMNAHTTSMN1; SMN2
SCHEMBL5485409 0.81 RAB9A (0.56) MAPTRAB9AGFERLMNAHTT
SCHEMBL5481486 0.74 LMNA (0.53) MAPTRAB9AGFERLMNAHTT
SCHEMBL5479006 0.72 RAB9A (0.52) MAPTRAB9AGFERLMNAHTT
SCHEMBL15693657 0.71 CYP2E1 (0.71) RAB9ALMNASMN1; SMN2NPC1CYP1A2
SCHEMBL5472730 0.71 MAPT (0.45) MAPTRAB9ALMNAGAAHRH4
SCHEMBL30687333 0.69 KMT2A (0.51) RAB9AHTTGAASMN1; SMN2NPC1
SCHEMBL9677090 0.69 HRH4 (0.55) MAPTRAB9ALMNATSHRHRH4
SCHEMBL5472719 0.69 PRMT5 (0.54) RAB9ALMNAHTTGAATSHR
SCHEMBL15693654 0.69 SMN1; SMN2 (0.69) MAPTRAB9ALMNAHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275995-A1 Thiobenzimidazole derivatives TEIJIN PHARMA LIMITED 2007-11-29 US disclosed
US-7268145-B2 Thiobenzimidazole derivatives TEIJIN PHARMA LIMITED (JP) 2007-09-11 US disclosed
US-20060040976-A1 Thiobenzimidazole derivatives TEIJIN LIMITED 2006-02-23 US disclosed
US-20050267148-A1 Benzimidazole derivative TEIJIN LIMITED 2005-12-01 US disclosed
EP-1097926-A1 THIOBENZIMIDAZOLE DERIVATIVES TEIJIN LIMITED (JP) 2001-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275995-A1 Thiobenzimidazole derivatives CMA1, SERPINB1, TMPRSS15 MAPT 4292/4885RAB9A 2783/4885GFER 4162/4885
US-20060040976-A1 Thiobenzimidazole derivatives CMA1, SERPINB1, TMPRSS15 MAPT 4292/4885RAB9A 2783/4885GFER 4162/4885
US-20050267148-A1 Benzimidazole derivative CMA1, SERPINB1, TPSAB1 MAPT 4269/4885RAB9A 3040/4885GFER 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.